Our portfolio
Exscientia

AI-enabled drug discovery platform

Exscientia plc, an AI-driven pharmaceutical company, is discovering, designing, and developing drugs quickly and efficiently, with three AI-designed drugs in Phase 1 human clinical trials. The foundation is supporting five Phase 1-ready small molecule therapeutics development — broad-spectrum antivirals for coronaviruses, influenza, and paramyxoviruses — to help prepare for future pandemics.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Active
  • Initial investment
    Public
  • Partnered in
    2021
  • Investment lead
    Chris Chen
  • Headquarters
    United Kingdom
  • Program strategy
    Discovery & Translational Sciences
Portfolio news
Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.